Adaptive Biotechnologies Third Quarter Financial Results - ADAPTIVE BIOTECHNOLOGIES CORP

Explicit Guidance:

• Full-Year 2026 MRD Revenue: Raised guidance range to $276–$286 million (from $268–$278 million); includes $9 million in milestones recognized in Q1 with no additional milestones assumed for the remainder of 2026. Midpoint represents 32% YoY growth or 41% growth excluding milestones.
• Full-Year 2026 Clinical Volume: Expects YoY growth of ~42% (updated from prior 38–40% guidance).
• Full-Year 2026 Operating Expenses: Expected to be ~$350 million (lower end of prior range), approximately 5% above 2025 levels.
• 2026 ASP: Expects full-year U.S. ASP of ~$1,400 per test.
• 2026 Pharma Sequencing Growth: Expects ~25% YoY growth (excluding milestones).
• 2027 Guidance: No specific financial guidance provided for 2027; management expects continued high-rate growth.
• EPS: No anticipation of GAAP net income or positive EPS for Q4 or Full Year 2026.

Business-Segment Outlook:

• MRD Clinical: Maintaining strong momentum with ~42% YoY volume growth expected for 2026; DLBCL and Multiple Myeloma identified as primary volume drivers.
• MRD Pharma: Backlog reached $270 million (up 34% YoY); Multiple Myeloma accounts for 65% of backlog and 79% of new bookings; 23 interventional studies utilizing ClonoSeq for MRD-guided therapy decisions.
• ASP Long-Term Targets: Conviction remains strong for achieving $1,700–$1,800 per test over the long term; potential to accelerate the timeline to reach this target range.
• Immune Medicine: Working with Morgan Stanley to advance separation process; path forward expected to be announced by year-end 2026.
• Expansion: Focus on blood-based testing (grew 68% YoY in Q3, now 51% of volume) and community adoption (37% of volume).

Market and Competitive Outlook:

• Multiple Myeloma: Regulatory tailwinds include updated NCCN guidelines specifying ClonoSeq as the preferred FDA-approved assay for 10^-6 sensitivity and a new definition of cure (5 years off treatment + 4 negative assessments) which explicitly requires next-gen sequencing at 10^-6 sensitivity.
• Reimbursement Strategy: Submitting technical assessment to Moldex for a maintenance bundle of five tests for Multiple Myeloma; active discussions ongoing.
• Competitive Moat: ClonoSeq is the only assay delivering 10^-6 sensitivity at clinical scale; management views competitive "noise" in DLBCL as disproportionately beneficial to market share.
• Market Penetration: 5,600 clinicians now order ClonoSeq (up 37% YoY), representing ~40% of U.S. hematology oncology providers; 78% of serial monitoring orders fulfilled in Flatiron-integrated accounts.

Macro / Industry Outlook:

• CMS/PAMA: Anticipate resolution of erroneous data submitted to CMS regarding PLA rates prior to November 2027 finalization; management believes PLA rate-setting will not impact the episodic billing structure (bundle of up to four tests) for Medicare.
• Regulatory: FDA draft guidance on MRD as an accelerated endpoint (Jan 2026) driving adoption; NCCN guidelines strengthening clinical rationale for MRD-guided therapy intensity decisions.
• Economic Environment: Management cites disciplined capital allocation and operating leverage as key drivers of profitability; no specific macroeconomic headwinds (rates, inflation) impacting short-term growth trajectory mentioned.

Strategic Initiatives:

• Reimbursement Catalysts: Submission to Moldex for maintenance bundle (targeting 2027 implementation); recurrence monitoring coverage submissions expected in first half of 2027 (CLL); data generation ongoing for Multiple Myeloma recurrence monitoring.
• Technology & R&D: Investing in AI-driven business process automation (revenue cycle), real-world data, and next-gen customer experience to facilitate serial testing; exploring new applications of the immunosequencing platform beyond hematology.
• Partnerships: Pfizer milestone payment received for rheumatoid arthritis data; Morgan Stanley partnership for business separation.
• Capacity/Operations: Transition to NovaSeqX driving gross margin expansion (sequencing gross margin up to 73%).
• Capital Deployment: As a profitable entity, profits will be reinvested to expand moats, deepen MRD adoption, and enhance product performance (e.g., blood-based assay performance). No specific M&A or buyback plans announced beyond general "disciplined" capital allocation.

Risks and Headwinds to Outlook:

• ASP Pressure: Increased testing frequency under the current Medicare bundle (4 tests per lifetime) is driving realized ASP pressure as patients exceed the bundle limit.
• Reimbursement Timing: No guarantee on the number of tests in the proposed maintenance bundle or the timing of Moldex approval.
• Milestone Revenue: Revenue is lumpy; no visibility into Q4 or 2027 milestone timing as these are dependent on external clinical trial readouts.
• GAAP Performance: Continued GAAP losses anticipated for Q4 and FY2026 despite profitability on an adjusted basis.

Management Tone on the Future:

• Confidence: High confidence in the long-term trajectory; "exciting inflection point" due to profitability; "tremendous internal excitement."
• Growth Outlook: Expect high-rate growth to continue into 2027 and beyond; no signs of slowing; "high ceiling remaining."
• Strategic Certainty: Strong conviction that the $1,700–$1,800 ASP target will be met, potentially accelerated; confident in the resolution of CMS data issues prior to rate finalization.
• Hedges: Standard SEC forward-looking statement disclaimers applied; specific hedges regarding exact reimbursement bundle sizes and timing.

Miscellaneous:

• Financial Profile: Achieved total company profitability in Q3; generated $8 million in free cash flow; ended quarter with $386 million in cash; $14.3 million in Adjusted EBITDA (GAAP net loss of $2.8 million).
• Clinical Metrics: Nearly 40,000 ClonoSeq tests performed in Q3; blood-based testing grew 68% YoY; community volume grew 14% sequentially.